Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

20152,785 citationsJournal Articlebronze Open Access

Authors

Christopher J. Sweeney · Johns Hopkins University

Yu‐Hui Chen · Dana-Farber Cancer Institute

Michael A. Carducci · Johns Hopkins University

Glenn Liu · University of Wisconsin Carbone Cancer Center

David F. Jarrard · Wisconsin Division of Public Health

Mario A. Eisenberger · Johns Hopkins University

Yu-Ning Wong

Abstract

Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00309985.).

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Prostate Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 8, pp. 737-746

DOI: 10.1056/nejmoa1503747

Field-Weighted Citation Impact: 185.45